Astellas Pharma : Presentation Material for Information Meeting (FY2021)

FY2021 FINANCIAL RESULTS

ENDED MARCH 31, 2022

Kenji Yasukawa, Ph.D.

President and CEO Astellas Pharma Inc. April 27, 2022

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice. Information about investigational compounds in development does not imply established safety or efficacy of the compounds; there is no guarantee investigational compounds will receive regulatory approval or become commercially available for the uses being investigated.

AGENDA

I

FY2021 Consolidated Financial Results

II

Initiatives for Sustainable Growth

III

FY2022 Forecasts and Key Expected Events

CSP2021 MAJOR PROGRESS IN Q4FY2021

Performance Goals

• 1. Revenue: XTANDI and Strategic products sales ≥¥1.2T in FY2025

• 2. Pipeline value: Focus Area projects expected sales ≥¥0.5T in FY2030

• 3. Core operating profit margin: ≥30% in FY2025

• • Obtained fezolinetant long-term safety data

• • Conducted 1st Sustainability Meeting

• • AT132 revision of the development plan

• • PADCEV approval in EU

• • ASP8731 and ASP3082 advanced to clinical stage

• • Updated Materiality Matrix

  Organizational Health Goals

  • 1. Enable patients to achieve better outcomes

  • 2. Translate innovative science into proven VALUE

  • 3. Advance the Rx+ Business

  • 4. Deepen engagement in sustainability

  Progress

  • • Introduction of shared objectives and ambitious objectives to divisional objective setting

  • • SG&A control

  • • Reorganization of commercial functions in order to centralize and standardize functions globally and build stronger capabilities

    • • Established "Astellas Leadership Expectations" and training commenced for all leaders (~3,000)

    Challenges

    • 1. Brave ideas pursue ambitious outcomes

    • 2. Talent and leadership thrives

    • 3. Excel as one Astellas

FY2021 FINANCIAL RESULTS: OVERVIEW

Record revenue increase for the first time since FY2018

Revenue increased 4% YoY and was slightly behind full-year forecast

 Sales of XTANDI and Strategic products increased 19% YoY, offsetting sales decrease due to termination of sales and distribution / transfer of product, but were behind ambitious full-year forecast aligned to CSP2021

 SG&A expenses were above full-year forecast R&D expenses were on track, but below full-year forecast when excluding one-off factors

Operating profit

 Core OP was behind full-year forecast due to promotion of standardization / rationalization investment for the future, temporary slowdown of XTANDI sales in Q4, and cost of sales increase due to rapid yen depreciation at end of FY2021  Full basis was also behind full-year forecast

•  Booked impairment losses on intangible assets and goodwill in Q4/FY2021 not included in full-year forecast :

  Review of AT132 development plan (31.2 billion yen), termination of development for ASP2390 (11.3 billion yen),

  and termination of development for ASP1951 (5.2 billion yen)

Strategic products: XOSPATA, PADCEV, EVRENZO

CSP2021: Corporate Strategic Plan 2021